Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

Thomas Yau,Vittorina Zagonel,Armando Santoro,Mirelis Acosta-Rivera,Su Pin Choo,Ana Matilla,Aiwu Ruth He,Antonio Cubillo Gracian,Anthony B. El-Khoueiry,Bruno Sangro,Tarek Eldawy,Jordi Bruix,Giovanni Luca Frassineti,Gina M. Vaccaro,Marina Tschaika,Christian Scheffold,Yun Shen,Jaclyn Neely,Fabio Piscaglia

Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

2020

Thomas Yau
Vittorina Zagonel
Armando Santoro
Mirelis Acosta-Rivera
Su Pin Choo
Ana Matilla
Aiwu Ruth He
Antonio Cubillo Gracian
Anthony B. El-Khoueiry
Bruno Sangro
Tarek Eldawy
Jordi Bruix
Giovanni Luca Frassineti
Gina M. Vaccaro
Marina Tschaika
Christian Scheffold
Yun Shen
Jaclyn Neely
Fabio Piscaglia

478Background: The programmed death-1 inhibitor NIVO had durable responses and a manageable safety profile in pts with aHCC in CheckMate 040 (NCT01658878; El-Khoueiry et al. Lancet 2017) and is app...

Keywords:

Hepatocellular carcinoma
Cabozantinib
Internal medicine
Checkmate
Combination therapy
Nivolumab
Ipilimumab
Oncology
Medicine
Pathology
in patient
safety profile

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations